Catheter Precision (VTAK) CEO Jenkins reports Series X preferred stock conversion
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Catheter Precision, Inc. reported an insider stock transaction by its Chairman and CEO, David A. Jenkins. On 12/05/2025, Jenkins converted shares of Series X Convertible Preferred Stock into common stock at a stated price of $0 per share. Following these conversions, he directly held 13,799 common shares, with an additional 34,579 shares held indirectly through a partnership and 109 shares held indirectly through a charitable remainder unitrust. The filing notes that the preferred stock has no expiration date and that some of the indirectly held shares are controlled via entities managed by Jenkins or his spouse, clarifying the structure of his beneficial ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
8,171.57 shares exercised/converted
Mixed
6 txns
Insider
JENKINS DAVID A
Role
Chairman of the Board and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series X Convertible Preferred Stock | 2,292.339 | $0.00 | -- |
| Conversion | Series X Convertible Preferred Stock | 5,860.54 | $0.00 | -- |
| Conversion | Series X Convertible Preferred Stock | 18.691 | $0.00 | -- |
| Conversion | Common Stock | 12,064 | $0.00 | -- |
| Conversion | Common Stock | 30,844 | $0.00 | -- |
| Conversion | Common Stock | 98 | $0.00 | -- |
Holdings After Transaction:
Series X Convertible Preferred Stock — 0 shares (Direct);
Series X Convertible Preferred Stock — 0 shares (Indirect, See Footnote);
Common Stock — 13,799 shares (Direct);
Common Stock — 34,579 shares (Indirect, See Footnote)
Footnotes (1)
- Shares held by a partnership of which the reporting person is the managing member of the managing partner Shares held by charitable remainder unitrust of which the reporting person's spouse is the trustee Series X Convertible Preferred Stock has no expiration date
